We believe that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs™. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms of Action™.
Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.
Remepy’s Digital Molecules™ are designed to be the software components within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug.
The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance.
Our apps include several additional key modules:
Remepy interventions have a two-pronged approach to improving patient outcomes. These precise interventions, together with drug molecules creates a new mechanism of action, in the form of a software-drug combination.
Psychological and cognitive interventions can restore neuro-endocrine and neuro-immunological balance by influencing hormones such as cortisol and adrenaline as well as cytokines such as IL-6 and INFγ.
This immunological rebalancing creates better conditions for improved pharmacokinetics and pharmacodynamics, directly enhancing efficacy and safety profiles of drugs.
Our evidence-based psychological interventions are also used to directly reduce comorbidities and medication side effects such as depression, anxiety, fatigue, and pain. This can have an overall improvement in patients' quality of life.
By reprogramming the adult brain, Remepy’s interventions can increase synaptic connectivity and influence brain areas that enhance patients’ ability to self-regulate and deal with negative emotions and pain.
Increased brain connectivity can help prevent excessive stress-related activation of the hypothalamic-pituitary axis, further rebalancing the immune system.
By rewiring the brain and balancing the immune system, our interventions foster optimal conditions for enhanced drug effect and improved disease outcomes in many neurodegenerative diseases, such as Alzheimer’s disease.
Remepy’s vision has been to enhance medicine by digitally invoking natural processes in our body.
There is a tremendous opportunity to rewrite the drug development process by harnessing the power of our digital world.
We have assembled a unique multidisciplinary team of software engineers, scientists, immunologists, physicians, psychologists, drug developers, computer scientists, and entrepreneurs to form a new kind of company, made possible by advances in technology, patient data and improved understanding of natural immune processes.
Head of Brain Cognition & Tech,
RU Institution, Harvard & HUJI
Chief Medical Officer & President of US Operations, Quark Pharmaceuticals